Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28052586 | 0.79 | ADORA2A (0.43) | ADORA2AADORA1ADORA3AADAT | |
| SCHEMBL6685170 | 0.77 | ADORA2A (0.42) | ADORA2AADORA1ADORA3AADAT | |
| SCHEMBL25957209 | 0.76 | ADORA2A (0.44) | ADORA2AADORA1LRRK2ADORA3 | |
| SCHEMBL1559316 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1LRRK2ADORA3AADAT | |
| SCHEMBL18068046 | 0.74 | ADORA2A (0.43) | ADORA2AADORA1LRRK2ADORA3AADAT | |
| SCHEMBL20885886 | 0.74 | ADORA2A (0.47) | ADORA2AADORA1LRRK2ADORA3AADAT | |
| SCHEMBL22536693 | 0.74 | ADORA2A (0.40) | ADORA2AADORA1ADORA3AADAT | |
| Hydrochloric Acid SCHEMBL3518233 | 0.74 | ADORA2A (0.40) | ADORA2AADORA1LRRK2ADORA3AADAT | |
| SCHEMBL19010796 | 0.74 | ADORA2A (0.35) | ADORA2AADORA1ADORA3 | |
| SCHEMBL20555524 | 0.74 | ADORA2A (0.30) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| CN-111433208-B | Pyrrolo (pyrazolo) pyrimidine derivatives as LRRK2 inhibitors | 奥斯考泰克公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| EP-3722298-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | Oscotec Inc. (KR) | 2020-10-14 | — | — | EP | disclosed |
| EP-3722298-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | Oscotec Inc. (KR) | 2020-10-14 | — | — | EP | disclosed |
| CN-111433208-A | Pyrrolo (pyrazolo) pyrimidine derivatives as L RRK2 inhibitors | 奥斯考泰克公司 | 2020-07-17 | — | — | CN | disclosed |
| WO-2019112269-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | 주식회사 오스코텍 | 2019-06-13 | — | — | WO | disclosed |
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2019-05-21 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2017106771-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | ADORA2A 2233/4885ADORA1 3976/4885LRRK2 1/4885 |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | LRRK2, PRKDC, DAPK2 | ADORA2A 2233/4885ADORA1 3976/4885LRRK2 1/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | ADORA2A 744/4885ADORA1 826/4885LRRK2 1/4885 |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | LRRK2, PARK7, WEE1 | ADORA2A 1839/4885ADORA1 928/4885LRRK2 1/4885 |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | LRRK2, PARK7, PAK3 | ADORA2A 1534/4885ADORA1 968/4885LRRK2 1/4885 |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | ADORA2A 2233/4885ADORA1 3976/4885LRRK2 1/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | ADORA2A 744/4885ADORA1 826/4885LRRK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.